NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report were sliding in early-afternoon trading on Friday as Citigroup analysts said sales of the Foster City, CA-based biopharmaceutical company's hepatitis-C treatments appear below analysts' expectations.
Data from IMS Health (IMS) this week showed Gilead's prescriptions for hepatitis-C medications were tracking below consensus at a decrease of approximately 14.3% quarter-over-quarter, Citigroup said, Barron's reports.
IMS doesn't track stocking, so inventory change data remain unclear, the firm noted. Additionally, new patient starts have fallen by 11% in the third quarter.
The firm said that it expects non-veterans affairs sales to come in between $1.3 billion and $1.4 billion vs. the $1.6 billion estimated for the last quarter.
"We estimate VA sales in 2Q'16 at ~$400M and believe they could be same for 3Q'16 given fixed budget. This gives us 3Q'16 IMS projected demand of $1.7-$1.8B," Citigroup continued in its analyst note, according to Barron's.
Citigroup maintained its "buy" rating and $105 price target on Gilead stock.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate GILEAD SCIENCES INC as a Buy with a ratings score of B. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: